Cite

HARVARD Citation

    Hofving, T. et al. (2019). 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition. Endocrine-related cancer. 26 (4), pp. 437-449. [Online]. 
  
Back to record